sanofi-aventis Pakistan limited

CONDENSED INTERIM FINANCIAL STATEMENTS FOR THE FIRST QUARTER ENDED 31 MARCH, 2015

(UN-AUDITED)





| 2 | Company Information                                 |
|---|---|
| 3 | Directors' Report to the Shareholders               |
| 5 | Condensed Interim Balance Sheet                     |
| 6 | Condensed Interim Profit & Loss Account             |
| 6 | Condensed Interim Statement of Comprehensive Income |
| 7 | Condensed Interim Cash Flow Statement               |
| 8 | Condensed Interim Statement of Changes in Equity    |
| 9 | Notes to the Condensed Interim Financial Statements |



#### **Board of Directors**

Syed Babar Ali Shakeel Mapara Arshad Ali Gohar Syed Hyder Ali Patrick Aghanian Francois Jean Louis Briens Jean-Marc Georges Mohammad Ibadullah Javed Iqbal

#### **Company Secretary**

Saad Usman

#### **Auditors**

Ernst & Young Ford Rhodes Sidat Hyder Chartered Accountants

#### Legal Advisors

Bilal Law Associates Ghani Law Associates Haidermota & Co.

#### Registrars & Share Transfer Office

FAMCO Associates (Pvt.) Ltd. 8-F, Next to Hotel Faran, Nursery, Block-6, P.E.C.H.S. Sharah-e-Faisal, Karachi - 74000. Tel. No: +92 21 34380101-5

Fax No: +92 21 34380106 URL: www.famco.com.pk Chairman

Acting Chief Executive

(Alternate Laila Khan) (Alternate Shakeel Mapara) (Alternate Mohammad Ali Hasani)

#### URL

www.sanofi.com.pk www.sanofidiabetes.com.pk

#### **Bankers**

Bank of Tokyo-Mitsubishi UFJ, Limited Barclays Bank PLC Citibank, N.A Deutsche Bank AG Habib Bank Limited MCB Bank Limited. National Bank of Pakistan Standard Chartered Bank

#### **Registered Office**

Plot 23, Sector 22, Korangi Industrial Area, Karachi - 74900

#### Postal Address

P.O. Box No. 4962, Karachi - 74000

### Contact

Tel: +92 21 35060221-35 contact.pk@sanofi.com

## Directors' Report to the Shareholders

The Board of Directors of sanofi-aventis Pakistan limited is pleased to present the un-audited interim condensed financial statements of your Company, for the 1st quarter ended March 31, 2015. These financial statements have been prepared in accordance with the requirements of the International Accounting Standard (IAS) 34 - "Interim Financial Reporting" and the provisions of and the directives issued under the Companies Ordinance, 1984. In case where requirements differ, the provision of directives issued under the Companies Ordinance, 1984 have been followed.

The net sales of the Company for the first quarter ended March 31, 2015, amounted to Rs.2,244 million, registering a decline of 0.6% over comparative prior period. The net sales of pharmaceutical business during the quarter reached Rs.1,974 million, recording a marginal decline of 3.2% over the comparative prior period. Vaccines and CHC recorded sales of Rs.118.3 million and Rs.41.3 million, growing by 30.3% and 25.4% respectively over the comparative prior period.

The Company further increased its foot hold in the export of pharmaceutical medicines in Afghanistan market as witnessed by the growth in sales achieved during the first quarter. The Company recorded export sales of Rs.110.6 million for the quarter, registering an increase of 17.3% over comparative prior period.

Gross margin as a percentage of net sales improved to 31.6% for the quarter ended respectively from 28.5% during the comparative prior period. The marginal improvementis primarily attributable to the significant appreciation of Pak Rupee versus the EUR – and in a lesser extent against US dollar, complemented by savings in rent, rates and taxes, security cost, travelling & conveyance which was partly offset by the negative elements such as higher repair and maintenance cost and depreciation. These negative elements shall be partially mitigated through cost cutting measures which are being adopted by the Company during the year.

Distribution and marketing expenses for the quarter increased by 16.4% over the comparative prior period while the administrative expenses increased by 1.2%. The expenses increased due to higher staff costs, depreciation, travelling and conveyance, repairs & maintenance and advertising & promotional activities.

Other operating cost for the quarter increased by 45.7% over the comparative prior period due to higher statutory levies based on profits. The exchange gain for the quarter increased by Rs.95.7 million over comparative period prior year, primarily due to significant appreciation of Pak Rupee versus the EUR –and in a lesser extent against US dollar. The Company's financing cost during the quarter increased by 30.2% over the comparative period, consequent to higher borrowings to support working capital requirements.

Profit before and after taxes for the quarter ended March 31, 2015 increased by Rs.61.6 million (43.3%) and Rs.55.4 million (72.4%) respectively over the comparative prior period because of the reasons explained above.

The Company devotes utmost importance to cash flow management and regularly monitors its day to day working capital and other financing requirements. During the three months the Company spent Rs.61.2 million on account of capital expenditure.



The Company expects that the growth of the pharmaceutical business during the year shall be close to market growth barring major unforeseen adverse events. The Company however, is concerned about the new pricing policy issued by the Drug Regulatory Authority of Pakistan (DRAP) wherein it has been recommended amongst other points, that the Maximum Retail Price (MRP) of all drugs be frozen at the approved level of MRP as on 31st October, 2013 which would remain at this level till 30th June 2016. In addition, DRAP has proposed to reduce the prices of life-saving and other drugs to the extent of 30% equally over a period of three years (i.e. 10% per annum).

The Company is closely monitoring the legal and business implications of the case and will take all necessary measures to ensure that the appropriate representations are made to the Government in support of a pricing policy acceptable to the industry.

On behalf of the Board of Directors, we would like to acknowledge the hard work put in by all the employees of the Company.

By order of the Board

Syed Babar Ali Chairman

Shakeel Mapara Acting Chief Executive



| MIL AS at March 31, 2015   |   |   |
|--|---|---|
| Note   | March 31,<br>2015   | December 31,<br>2014  |
|  | Rupee<br>(Un-audited)   | es in `000<br>(Audited)   |
| <u>ASSETS</u>  |   |   |
| NON-CURRENT ASSETS   |   |   |
| Fixed assets Property, plant and equipment 4 Intangible asset  | 2,002,415<br>   | 2,018,562<br>220<br>2,018,782   |
| Long-term loans<br>Long-term deposits  | 7,226<br>4,030  | 7,737<br>4,030  |
| CURRENT ASSETS Stores and spares Stock-in-trade Trade debts Short-term loans and advances Trade deposits and short-term prepayments Other receivables Taxation Cash at banks | 48,977<br>4,063,661<br>975,136<br>65,977<br>211,839<br>45,815<br>844,252<br>26,239<br>6,281,896 | 49,471<br>3,758,056<br>733,717<br>49,250<br>218,792<br>178,899<br>804,733<br>9,280<br>5,802,198 |
| TOTAL ASSETS   | 8,295,757   | 7,832,747   |
| EQUITY AND LIABILITIES   |   |   |
| SHARE CAPITAL AND RESERVES Share capital Authorized 10,000,000 Ordinary shares of Rs. 10 each  | 100,000   | 100,000   |
| Issued, subscribed and paid-up   | 96,448  | 96,448  |
| Reserves Capital reserves Revenue reserves   | 193,352<br>2,238,687<br>2,432,039<br>2,528,487  | 188,982<br>2,106,717<br>2,295,699<br>2,392,147  |
| NON-CURRENT LIABILITIES Long term financing Deferred taxation  CURRENT LIABILITIES   | 500,000<br>132,908<br>632,908   | 500,000<br>132,276<br>632,276   |
| Trade and other payables Accrued mark-up Short term borrowings Running finances utilized under mark-up   | 1,871,702<br>79,779<br>600,000  | 1,991,679<br>67,778<br>600,000  |
| arrangements - secured   | 2,582,881   | 2,148,867   |
|  | 5,134,362   | 4,808,324   |
| CONTINGENCIES AND COMMITMENTS 5  | 5,767,270   | 5,440,600   |
| TOTAL EQUITY AND LIABILITIES   | 8,295,757   | 7,832,747   |
|  |   |   |

The annexed notes 1 to 10 form an integral part of these financial statements.

Syed Babar Ali Chairman

Shakeel Mapara Acting Chief Executive



## Condensed Interim Profit and Loss Account For the first quarter ended March 31, 2015 (Un-audited)

|  | March 31, 2015  | March, 31 2014   |  |  |  |  |
|--|---|--|--|--|--|--|
|  | Rupees in `000  |  |  |  |  |  |
|  | ·   |  |  |  |  |  |
| NET SALES  | 2,244,276   | 2,256,792  |  |  |  |  |
| Cost of sales  | (1,535,517)   | (1,612,545)  |  |  |  |  |
| GROSS PROFIT   | 708,759   | 644,247  |  |  |  |  |
| Distribution and marketing expenses<br>Administrative expenses<br>Other operating expenses<br>Other income | (498,542)<br>(56,961)<br>(22,070)<br>162,548<br>(415,025) | (428,141)<br>(56,272)<br>(15,139)<br>66,596<br>(432,956) |  |  |  |  |
| OPERATING PROFIT   | 293,734   | 211,291  |  |  |  |  |
| Finance costs  | (89,719)  | (68,889)   |  |  |  |  |
| PROFIT BEFORE TAXATION FOR THE PERIOD  | 204,015   | 142,402  |  |  |  |  |
| Taxation - Current<br>- Prior<br>- Deferred  | (71,413)<br>-<br>(632)                                    | (41,334)<br>(11,663)<br>(12,857)                         |  |  |  |  |
| NET PROFIT FOR THE PERIOD  | (72,045)<br>131,970                                       | (65,854)<br>76,548                                       |  |  |  |  |
| BASIC EARNINGS<br>PER SHARE (Rupees)   | 13.68   | 7.94   |  |  |  |  |

The annexed notes 1 to 10 form an integral part of these financial statements.

Syed Babar Ali Chairman

Chairman

Shakeel Mapara Acting Chief Executive

Karachi: April 28, 2015.

Condensed Interim Statement of
Comprehensive Income
For the first quarter ended March 31, 2015 (Un-audited)

|  | March 31, 2015 | March, 31 2014 |
|--|----------------|----------------|
|  | Rupees ir      | n `000         |
| Net profit for the period                          | 131,970        | 76,548         |
| Other comprehensive income / (loss) for the period | <del>-</del>   | -              |
| Total comprehensive income for the period          | 131,970        | 76,548         |

The annexed notes 1 to 10 form an integral part of these financial statements.

Syed Babar Ali Chairman

Shakeel Mapara Acting Chief Executive





| No  | March 31,<br>ote 2015                                 | March 31,<br>2014<br>Lupees in `000         |
|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVIT   | ES  |   |
| Cash generated from operations Finance costs paid Income tax paid Retirement benefits paid Long-term loans and advances (net) | (155,262)<br>(77,718)<br>(110,932)<br>(14,101)<br>511 | 510,774<br>(73,797)<br>(68,682)<br>-<br>109 |
| Net Cash (used in) / generated from operating activities  | (357,502)   | 368,404                                     |
| CASH FLOWS FROM INVESTING ACTIVITIE   | ES  |   |
| Capital expenditure Sale proceeds from disposal of operating  | (61,159)  | (48,835)                                    |
| fixed assets  | 1,623   | 763   |
| Net cash used in investing activities   | (59,536)  | (48,072)                                    |
| CASH FLOWS FROM FINANCING ACTIVITIES Dividends paid   | ES (17)   | (2)   |
| NET (DECREASE) / INCREASE IN CASH<br>AND CASH EQUIVALENTS   | (417,055)   | 320,330                                     |
| CASH AND CASH EQUIVALENTS AT<br>BEGINNING OF THE PERIOD   | (2,139,587)   | (1,558,937)                                 |
| CASH AND CASH EQUIVALENTS AT<br>END OF THE PERIOD 7   | (2,556,642)   | (1,238,607)                                 |

The annexed notes 1 to 10 form an integral part of these financial statements.

Syed Babar Ali Chairman

Shakeel Mapara Acting Chief Executive



# Condensed Interim Statement of Changes in Equity For the first quarter ended Marchr 31, 2015 (Un-audited)

|   |   | Capital Reserves                       |   |                      | Revenue f          |                               |           |
|---|---|--|---|----------------------|--------------------|-------------------------------|-----------|
|   | Issued,<br>subscribed<br>and<br>paid-up<br>share<br>capital | Long<br>term<br>liabilities<br>forgone | Difference<br>of share<br>capital<br>under<br>scheme of<br>arrangement<br>for<br>amalgamation | Other<br>ees in '000 | General<br>reserve | Unapprop-<br>riated<br>profit | Total     |
| Balance as at January 1, 2014                               | 96,448  | 5,935                                  | 18,000  | 129,403              | 1,535,538          | 441,289                       | 2,226,613 |
| Employee benefits cost under IFRS - 2 "Share based payment" | =   | -                                      | -   | 7,378                | -                  | -                             | 7,378     |
| Transfer to general reserve                                 | -   | -                                      | -   | -                    | 200,000            | (2,00,000)                    | -         |
| Net profit for the period                                   | -   | -                                      | -   | -                    | -                  | 76,548                        | 76,548    |
| Other comprehensive income for the period                   |   | -                                      | _   | -                    | -                  | -                             | _         |
| Total comprehensive income for the period                   | -   | -                                      | -   | -                    | -                  | 76,548                        | 76,548    |
| Balance as at March 31, 2014                                | 96,448  | 5,935                                  | 18,000  | 136,781              | 1,735,538          | 317,837                       | 2,310,539 |
| Balance as at January 1, 2015                               | 96,448  | 5,935                                  | 18,000  | 165,047              | 1,735,538          | 371,179                       | 2,392,147 |
| Employee benefit cost under IFRS 2 - "Share based Payment"  | =   | -                                      | =   | 4,370                | -                  | -                             | 4,370     |
| Transfer to general reserve                                 |   |  |   |                      | 200,000            | (200,000)                     |           |
| Net profit for the period                                   | -   | -                                      | -   | -                    | -                  | 131,970                       | 131,970   |
| Other comprehensive income for the period                   | _   | -                                      | _   | -                    | -                  | _                             | -         |
| Total comprehensive income for the period                   | -   | -                                      | -   | -                    | -                  | 131,970                       | 131,970   |
| Balance as at March 31, 2015                                | 96,448  | 5,935                                  | 18,000  | 169,417              | 1,935,538          | 303,149                       | 2,528,487 |
|   |   |  |   |                      |                    |                               |           |

The annexed notes 1 to 10 form an integral part of these financial statements.

Chairman

Shakeel Mapara Acting Chief Executive



#### 1. THE COMPANY AND ITS OPERATIONS

The Company was incorporated in Pakistan in 1967 under the Companies Act, VII of 1913 (now the Companies Ordinance, 1984), as a Public Limited Company. The shares of the Company are listed on Karachi, Lahore and Islamabad Stock Exchanges. It is engaged in the manufacturing and selling of pharmaceutical and consumer products.

The registered office of the Company is located at Plot 23, Sector 22, Korangi Industrial Area, Karachi.

#### 2. STATEMENT OF COMPLIANCE

These condensed interim financial statements of the Company for the first quarter ended March 31, 2015 have been prepared in accordance with the requirements of the International Accounting Standard (IAS) – 34, "Interim Financial Reporting" and provisions of and directives issued under the Companies Ordinance, 1984. In case where requirements differ, the provisions of or directives issued under the Companies Ordinance, 1984 have been followed. These are required to be presented to the shareholders under section 245 of the Companies Ordinance, 1984.

These condensed interim financial statements are unaudited and do not include all the information and disclosures as required in the annual financial statements and should be read in conjunction with the Company's annual financial statements for the year ended December 31, 2014.

#### 3. ACCOUNTING POLICIES

#### 3.1 SIGNIFICANT ACCOUNTING POLICIES

The accounting policies and the methods of computation adopted in the preparation of these condensed interim financial statements are the same as those applied in the preparation of the financial statements for the year ended December 31, 2014.

| March 31,<br>2015 | 2014      |
|-------------------|-----------|
| Rupees i          | n `000    |
| (Un-audited)      | (Audited) |

#### 4. PROPERTY, PLANT AND EQUIPMENT

| Operating fixed assets   | 4.1 | 1,788,061 | 1,822,726 |
|--------------------------|-----|-----------|-----------|
| Capital work-in-progress |     | 214,354   | 195,836   |
|                          |     | 2,002,415 | 2,018,562 |

#### 4.1 Operating fixed assets

Following were the additions and disposals of operating fixed assets during the current period:

|                              |           | Dispo                   | osals                       |
|------------------------------|-----------|-------------------------|-----------------------------|
|                              | Additions | Cost<br>Rupees in `000. | Accumulated<br>Depreciation |
| Building                     | 754       | -                       | _                           |
| Plant and machinery          | 1,988     | =                       | -                           |
| Furniture and fixtures       | 884       | -                       | -                           |
| Factory and office equipment | 17,281    | 2,844                   | 2,844                       |
| Motor vehicles - owned       | 191       | 3,912                   | 3,594                       |
|                              | 21,098    | 6,756                   | 6,438                       |

#### 5. CONTINGENCIES AND COMMITMENTS

#### Contingencies

- 5.1 Claims not acknowledged as debt amounted to Rs. 6.200 (December 31, 2014:Rs. 6.200) million at the end of the current period.
- 5.2 There is no change in the status of contigencies in respect of income tax assessments, as set out in note 20.1 (b) to the annual financial statements of the Company for the year ended December 31, 2014.



- 5.3 Commitments in respect of capital expenditure contracted for amounted to Rs. 58.303 (December 31, 2014:Rs. 36.581) millon at the end of the first quarter.
- 5.4 Post dated cheques aggregating to Rs. 20.694 (December 31, 2014: Rs. 27.634) million at the end of the current period have been given to Collector of Customs in respect of exemption of levies on import of machine accessories.

|    |   | March 31,<br>2015   | December 31,<br>2014  |
|----|---|---|---|
|    |   | Rupees i<br>(Un-audited)                                      | n `000<br>(Audited)   |
|    | 5.5 Outstanding letters of credit   | 88,719  | 112,817   |
|    | 5.6 Outstanding bank contracts  | 312,709   | 225,944   |
|    |   | March 31,<br>2015   | March 31,<br>2014   |
|    | Note  | eRupee  | es in `000  |
| 6. | CASH GENERATED FROM OPERATIONS  | 004.045   | 440.400   |
|    | Profit before taxation  | 204,015   | 142,402   |
|    | Adjustment for non-cash charges and other items: Depreciation / amortization Gain on disposal of operating fixed assets Fixed assets written off Expenses arising from equity settled share | 75,775<br>(1,305)<br>1,243                                    | 55,398<br>(713)   |
|    | based payment plans Retirement benefits Finance costs Working capital changes 6.1   | 4,370<br>14,101<br>89,719<br>(543,180)                        | 7,378<br>12,646<br>68,889<br>224,774                        |
|    |   | (155,262)   | 510,774   |
|    | 6.1 Working capital changes   |   |   |
|    | Decrease / (Increase) in current assets:  |   |   |
|    | Stores and spares Stock-in-trade Trade debts Short-term loans and advances Trade deposits and short-term prepayments Other receivables - net  | 494<br>(305,605)<br>(241,419)<br>(16,727)<br>6,953<br>133,084 | 102<br>(124,737)<br>186,610<br>(15,870)<br>9,696<br>331,781 |
|    | Decrease in current liabilities:  | (423,220)   | 387,582   |
|    | Trade and other payables - net<br>(excluding unclaimed dividend)  | (119,960) (543,180)   | (162,808)<br>224,774  |
| 7. | CASH AND CASH EQUIVALENTS  Cash and cash equivalents comprise of the following items:   |   |   |
|    | Cash and bank balance   | 26,239  | 17,615  |
|    | Running finance utilized under mark-up<br>arrangements  | (2,582,881)   | (1,256,222)   |
|    |   | (2,556,642)   | (1,238,607)   |
|    |   |   |   |



#### 8. TRANSACTIONS WITH RELATED PARTIES

Related parties comprise of associated undertakings, employees' provident fund, employees' gratuity fund, employees' pension fund, directors and key management personnel of the Company. The Company in the normal course of business carries out transactions with various related parties.

There are no transactions with key management personnel other than under the terms of employment.

Details of transactions with related parties during the period are as follows:

|      |   | March 31, 2015 |   |                                 |                   |                          | March 31, 2014 |   |                                 |                   |         |
|------|---|----------------|---|---------------------------------|-------------------|--------------------------|----------------|---|---------------------------------|-------------------|---------|
|      |   |                | Associated<br>undertaking<br>by virtue<br>of common<br>directorship | Retirement<br>benefits<br>plans | ment<br>personnel | Total                    |                | Associated undertaking by virtue of common directorship | Retirement<br>benefits<br>plans | ment<br>personnel | Total   |
| i)   | Gross Sales   | 2,722          | -   | -                               | -                 | 2,722                    | 3,520          | -   | -                               | -                 | 3,520   |
| ii)  | Purchase of goods   | 936,197        | -   | -                               | -                 | 936,197                  | 838,449        | -   | -                               | •                 | 838,449 |
| iii) | Purchase of services  |                | 8,061   | -                               |                   | 8,061                    | -              | 9,573   | -                               | •                 | 9,573   |
| iv)  | Contribution paid - Provident fund - Gratuity fund - Pension fund | -              | :   | 10,863<br>8,474<br>5,628        | :                 | 10,863<br>8,474<br>5,628 |                | :   | 9,552                           | -                 | 9,552   |
| v)   | Remuneration of key<br>management person                          | nel -          |   | -                               | 45,021            | 45,021                   | -              | -   | -                               | 34,032            | 34,032  |

Further, the impact of benefits to the Chief Executive and others recognized by the Company in the expenses during the period on account of share-based payment plans aggregated to Rs. 0.404 (March 31, 2014: Rs. 1.334) million and Rs. 3.966 (March 31, 2014: Rs. 6.044) million, respectively.

#### 9. DATE OF AUTHORIZATION FOR ISSUE

These condensed interim financial statements were authorized for issue on April 28, 2015 by the Board of Directors of the Company.

#### 10. GENERAL

Figures presented in these condensed interim financial statements have been rounded off to the nearest thousand rupees, unless otherwise stated.

Syed Babar Ali Chairman

Shakeel Mapara Acting Chief Executive